One-Year Follow-Up of Vascular Intervention Trials Disrupted by the COVID-19 Pandemic: A Use-Case landscape.

Cardiovasc Revasc Med · 2022 · PMC9323208 · PMID 35953406

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

top 81.3 million with 992,000 deaths with many of the patients previously infected with COVID-19 able to be re-infected or to experience “long-COVID”, there is likely to be significant overlap between COVID-related outcomes and clinical trial outcomes.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.